<!DOCTYPE html>
<html>

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <meta charset="utf-8">
    <meta name="format-detection" content="telephone=no">

<style type="text/css">

</style>
</head>

<body style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background-color: #ffffff; margin: 0; padding: 0" bgcolor="#e8e8ea">
    
<style>
    body {
        font-family: Arial;
    }
    /* This limits the width of the select boxes with the Veeva interface so as not to break the layout */
    
    select {
        max-width: 485px;
    }
 </style>
    
    
    <div style="display:none;font-size:1px;color:#ffffff;line-height:1px;max-height:0px;max-width:0px;opacity:0;overflow:hidden;">A message from Amgen Oncology</div>
    
   <table cellspacing="0" cellpadding="0" bgcolor="#ffffff" width="550" border="0" style="border-spacing: 0;border-collapse: collapse;font-family: Arial;" align="center">
        <tr>
            <td>
                <table cellspacing="0" cellpadding="0">
                    <tr>
                        <td width="320" style="background: #dce467;text-transform: uppercase;font-weight: bold;color: #0073ae;font-size: 11px;padding:20px 0;text-align: center;border-right:2px solid #ffffff;font-family: Arial, HelveticaNeue, Helvetica, sans-serif;">
                            <a style="color:#0073ae;text-decoration: none" href="http://pi.amgen.com/united_states/imlygic/imlygic_mg.pdf" target="_blank">Prescribing Information &amp; Medication Guide &gt;</a>
                        </td>
                        <td width="228" style="background: #dce467;text-transform: uppercase;font-weight: bold;color: #0073ae;font-size: 11px;padding:20px 0;margin-left:20px;text-align: center;padding-left: 2px;font-family: Arial, HelveticaNeue, Helvetica, sans-serif;">
                            <a style="color:#0073ae;text-decoration: none" href="http://www.imlygic.com/#isi" target="_blank">Important Safety Information &gt;</a>              
                            
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
        <tr>
            <td style="padding-left: 25px; padding-right: 22px;padding-top:25px;color:#000000;font-family: Arial, HelveticaNeue, Helvetica, sans-serif;font-size: 18px" width="500">
                <strong style="font-size: 20px;color:#0073ae">IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> IS FDA APPROVED</strong>
                <br style="line-height: 2">
                For the treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">1</sup>
            </td>
       </tr>
       <tr>
            <td style="text-align: center;padding-top: 25px">
                <a href="http://www.imlygic.com" target="_blank"><img src="logo.png" style="margin-top: 3px;margin-bottom: 0px;width: 450px;border:none"></a>
            </td>           
           <tr>
            <td style="padding-left: 25px; padding-right: 25px;padding-top:35px;color:#000000;font-size: 18px" width="500">

                {{customText[ Hello | Hi | Dear | Greetings]}} {{customText[ Dr. | Mr. | Ms. ]}} {{accLname}},
                <br><br>
                <!--  MAIN TEXT  -->
                   I would like to schedule an appointment with you to discuss the IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> Cost Cap Program. 
                <!--  MAIN TEXT  -->
                <br><br>
                   {{customText[If you have any questions, please feel free to contact me. | I look forward to our next meeting. | I look forward to our upcoming meeting. | I’ll be in touch to set up our next meeting. | Please contact me at the phone number below with any questions. | Please let me know when you are available to meet.]}}
                <br><br>
                    {{customText [Sincerely, | Thank you, | Regards, | Talk to you soon, ]}}<br><br><br>
                    RepName<br>
                    Amgen Oncology<br>
                    Phone Number
            </td>
        </tr>
        <!-- references -->
        <tr style="margin-top: 20px">
            <td style="padding-left: 25px; padding-right:20px; padding-top:25px;padding-bottom:35px;font-size: 17px;">
                <strong>Reference: 1.</strong> IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> (talimogene laherparepvec) Prescribing Information, BioVex, Inc., a subsidiary of Amgen Inc.
            </td>
        </tr>      

        <tr>
            <td width="500" style="padding-left: 25px; padding-right: 25px;padding-top:35px;color: #ffffff;font-size: 18px; background:#005678">
                <strong>Please see full <a href="http://pi.amgen.com/united_states/imlygic/imlygic_pi.pdf" target="_blank" style="color:#dce467">Prescribing Information</a>, and <a href="http://pi.amgen.com/united_states/imlygic/imlygic_mg.pdf" target="_blank"  style="color:#dce467">Medication Guide</a>, for IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup></strong>
                <br><br>
                    <strong style="text-transform: uppercase">Indication</strong><br />
                    IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
                <br><br>
                Limitations of use: IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> has not been shown to improve overall survival or have an effect on visceral metastases.
                <br><br>
                <strong>IMPORTANT SAFETY INFORMATION 
                <br>
                Contraindications</strong><br>
                <table style="font-family: arial; font-size: 18px;color:#ffffff" border="0">
                    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">Do not administer IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.</td>
                    </tr>
<tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">Do not administer IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> to pregnant patients.</td>
                    </tr> 
                    </table>
                <br>
                <strong>Warnings and Precautions </strong>
                
<table style="font-family: arial; font-size: 18px;color:#ffffff" border="0">
   <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;"><strong>Accidental exposure to IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup></strong> may lead to transmission of IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. The affected area in exposed individuals should be cleaned thoroughly with soap and water and/or a disinfectant.</td>
                    </tr>
                    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">Caregivers should wear protective gloves when assisting patients in applying or changing occlusive dressings and observe safety precautions for disposal of used dressings, gloves, and cleaning materials. Exposed individuals should clean the affected area thoroughly with soap and water and/or a disinfectant.</td>
                    </tr>
                    
                    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">To prevent possible inadvertent transfer of IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> to other areas of the body, patients should be advised to avoid touching or scratching injection sites or occlusive dressings.</td>
                    </tr>                    
                    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;"><strong>Herpetic infections:</strong> Herpetic infections (including cold sores and herpetic keratitis) have been reported in IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>-treated patients. Disseminated herpetic infection may also occur in immunocompromised patients. Patients who develop suspicious herpes-like lesions should follow standard hygienic practices to prevent viral transmission. 
</td>
                    </tr>                    
    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
    <td style="line-height: 1.333;color:#ffffff;">Patients or close contacts with suspected signs or symptoms of a herpetic infection should contact their health care provider to evaluate the lesions. Suspected herpetic lesions should be reported to Amgen at 1-855-IMLYGIC <span style="white-space: nowrap">(1-855-465-9442).</span> Patients or close contacts have the option of follow-up testing for further characterization of the infection.</td>
                    </tr>                    
    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> is sensitive to acyclovir. Acyclovir or other antiviral agents may interfere with the effectiveness of IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>. Consider the risks and benefits of IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> treatment before administering antiviral agents to manage herpetic infection.
</td>
                    </tr>                    
    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;"><strong>Injection Site Complications:</strong> Necrosis or ulceration of tumor tissue may occur during IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> treatment. Cellulitis and systemic bacterial infection have been reported in clinical studies. Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.</td>
                    </tr>                    
    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">Impaired healing at the injection site has been reported. IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> may increase the risk of impaired healing in patients with underlying risk factors (eg, previous radiation at the injection site or lesions in poorly vascularized areas). If there is persistent infection or delayed healing of the injection site, consider the risks and benefits of continuing treatment.
</td>
                    </tr>                    
    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;"><strong>Immune-Mediated events</strong> including glomerulonephritis, vasculitis, pneumonitis, worsening psoriasis, and vitiligo have been reported in patients treated with IMLYGIC®. Consider the risks and benefits of IMLYGIC® before initiating treatment in patients who have underlying autoimmune disease or before continuing treatment in patients who develop immune-mediated events.
</td>
                    </tr>                    
                    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;"><strong>Plasmacytoma at Injection Site:</strong> Plasmacytoma in proximity to the injection site has been reported in a patient with smoldering multiple myeloma after IMLYGIC administration in a clinical study. Consider the risks and benefits of IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> in patients with multiple myeloma or in whom plasmacytoma develops during treatment.</td>
                    </tr>                   
                </table>
                    <br>
                    <strong>Adverse Reactions</strong>
                <table style="font-family: arial; font-size: 18px;color:#ffffff;border-collapse: collapse" border="0">
                    <tr>
                        <td style="color:#ffffff; vertical-align: top">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;">The most commonly reported adverse drug reactions <span style="white-space: nowrap">(&ge; 25%)</span> in IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain. Pyrexia, chills, and influenza-like illness can occur at any time during IMLYGIC<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup> treatment, but were more frequent during the first 3 months of treatment.</td>
                    </tr>
                    <tr>
                        <td style="color:#ffffff; vertical-align: top;padding-bottom: 30px">&#x25cf;</td>
                        <td style="line-height: 1.333;color:#ffffff;padding-bottom: 30px">The most common Grade 3 or higher adverse reaction was cellulitis.</td>
                    </tr>
                </table>
            </td>
        </tr>
        <!-- footer -->
        <tr>
            <td width="500" bgcolor="#0073ae" style="color: #ffffff; font-size: 12px; padding: 8px 25px;line-height: 1.2">
                <table style="padding:0px 0px 0px">
                    <tr>
                        <td width="50%" style="font-size:14px;color:#ffffff;padding-top:10px;padding-bottom: 20px">
                            <a href="http://www.amgen.com" style="border: none;"><img src="logo-amgen.png" alt="AMGEN" style="border:none"/></a>
                        </td>
                        
                    </tr>
                    <tr>
                        <td style="font-size:14px;color:#ffffff;">
                            <b style="font-size: 18px;">Amgen</b><br />
                            One Amgen Center Drive<br />
                            Thousand Oaks, CA 91320-1799
                            <br />
                        </td>
                        <td width="236" height="10" style="background:#dce467;color:#558476;font-size: 22px;text-align:center;font-weight:bold">
                            <a href="http://www.imlygic.com/" target="_blank" style="color:#0073ae;text-decoration: none;font-size:22px;">LEARN MORE &gt;</a>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="2" style="top: -4px; position: relative;font-size:14px">
                            <a href="http://www.amgen.com" title="www.amgen.com" target="blank" style="color:#ffffff;text-decoration:none;">www.amgen.com</a>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="2" style="padding-bottom:18px;font-size:14px;color:#ffffff;">
                            &copy; 2016 Amgen Inc. All rights reserved. USA-678-129501
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
        <tr bgcolor="#ffffff">
            <td style="color: #666666; font-size: 14px; padding: 8px 25px;line-height: 1.2;" bgcolor="#ffffff" width="500">
                <p style="margin-bottom: 8px;">
                    <a style="color:#666666;text-decoration:underline;" href="#" title="Unsubscribe" target="blank">Click here</a> to unsubscribe to future emails
                </p>
                <a style="color:#666666;text-decoration:none;" href="http://wwwext.amgen.com/privacy-statement/" title="Privacy Statement" target="blank">Privacy Statement</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                <a style="color:#666666;text-decoration:none;" href="http://wwwext.amgen.com/terms-of-use/" title="Terms of Use" target="blank">Terms of Use</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                <a style="color:#666666;text-decoration:none;" href="http://www.amgen.com/contact-us/" title="Contact Us" target="blank">Contact Us</a>
            </td>
        </tr>
    </table>
</body>
</html>